NuScale Drops 6% as $75K Quarterly Revenue and New $750M Offering Deepen Dilution Risk

What happened

NuScale Power shares fell 6% to $8.66 after reporting second-quarter revenue of just $75,000 and disclosing a new $750 million equity offering. The revenue collapse from $21.4 million in the prior-year half to $0.64 million in 1H26 reflects the end of RoPower FEED work and zero binding module sales, while the company still lost $121.5 million from operations in the first half. The balance sheet remains liquid with $1.9 billion in cash and investments and no debt, but that strength was built almost entirely on equity issuance—$984.5 million raised in the first half plus this new $750 million sale—lifting Class A shares from 318.5 million to over 410 million. Commercialization remains gated by two unresolved items: a non-binding TVA/ENTRA1 arrangement still contingent on a power purchase agreement, and Romania’s Nuclearelectrica reporting no concrete progress on post-FID financing. Cash burn is also structural, with a $259.9 million ENTRA1 milestone payment already made in 1H26 before any firm customer revenue, making the stock a story of licensing optionality increasingly diluted by financing.

Implication

The fresh $750 million offering increases the probability of the bear scenario (implied $7) because it signals management’s continued reliance on equity rather than customer cash, directly reducing per-share value. Our base case of $10 assumed no further material dilution before a binding contract; that assumption is now under pressure, and we would trim our base case toward $9 until the offering is priced. The decline to $8.66 provides no margin of safety relative to bear value, but it is only 8% above our $8 entry, so existing holders should avoid panic selling and new buyers should wait for either a definitive TVA PPA or Romanian pre-EPC financing. Monitor the next two quarterly reports for any additional ATM usage or milestone payments to ENTRA1 without a corresponding customer contract, as these would undermine the liquidity narrative and push the thesis toward exit. A sustained move above $13 would require exactly the catalyst absent today—a binding off-take agreement—and until that appears, we see asymmetric downside from continued dilution.

Thesis delta

The new $750 million stock sale marks a material negative shift: it compounds the 1H26 dilution of $984.5 million and signals that the company still cannot fund itself from customer receipts. This raises the probability of our bear case ($7) and lowers our base-case implied value from $10 to roughly $9, but we keep our WAIT rating because the stock now trades near our $8 entry threshold. A re-rating to AVOID would require evidence that additional share issuance is being used to fund ENTRA1 milestones without any binding PPA by early 2027.